Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer

NCT01105312 is registered in ClinicalTrials.gov with Alliance for Clinical Trials in Oncology as lead sponsor.

NCT NCT01105312
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01105312 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I/II Study of Panobinostat (LBH589) and Letrozole in Patients With Triple Negative Metastatic Breast Cancer
Lead sponsor
Alliance for Clinical Trials in Oncology
Phase
Phase 1/2
Overall status
Completed
Start date
September 30, 2010
Completion date
September 3, 2013
Enrollment
28 (actual)
Sites
172

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer